Sanara MedTech annual operating margin
2010
2011
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanara MedTech's operating margin was 7.08% for fiscal 2025.
View full Sanara MedTech company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 7.08% | +5.63 pp |
| 2024 | 2024-12-31 | 1.45% | +7.94 pp |
| 2023 | 2023-12-31 | −6.49% | +20.82 pp |
| 2022 | 2022-12-31 | −27.30% | +3.25 pp |
| 2021 | 2021-12-31 | −30.55% | +1.75 pp |
| 2020 | 2020-12-31 | −32.30% | −9.01 pp |
| 2019 | 2019-12-31 | −23.29% | −14.69 pp |
| 2018 | 2018-12-31 | −8.60% | −10.51 pp |
| 2017 | 2017-12-31 | 1.91% | +6.85 pp |
| 2016 | 2016-12-31 | −4.94% | +23.68 pp |
| 2015 | 2015-12-31 | −28.62% | +198.33 pp |
| 2011 | 2011-12-31 | −226.95% | +44.99 pp |
| 2010 | 2010-12-31 | −271.94% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 6.33% | −3.31 pp |
| Q1 2026 | 2026-03-31 | 9.52% | +6.00 pp |
| Q4 2025 | 2025-12-31 | 3.81% | −14.80 pp |
| Q3 2025 | 2025-09-30 | 11.17% | +7.58 pp |
| Q2 2025 | 2025-06-30 | 9.64% | +23.95 pp |
| Q1 2025 | 2025-03-31 | 3.52% | +11.79 pp |
| Q4 2024 | 2024-12-31 | 18.62% | +19.89 pp |
| Q3 2024 | 2024-09-30 | 3.59% | +9.25 pp |
| Q2 2024 | 2024-06-30 | −14.31% | −2.46 pp |
| Q1 2024 | 2024-03-31 | −8.26% | −0.43 pp |
| Q4 2023 | 2023-12-31 | −1.28% | +19.11 pp |
| Q3 2023 | 2023-09-30 | −5.66% | +19.12 pp |
| Q2 2023 | 2023-06-30 | −11.85% | +23.16 pp |
| Q1 2023 | 2023-03-31 | −7.84% | +27.71 pp |
| Q4 2022 | 2022-12-31 | −20.39% | +28.13 pp |
| Q3 2022 | 2022-09-30 | −24.78% | +7.06 pp |
| Q2 2022 | 2022-06-30 | −35.00% | −18.65 pp |
| Q1 2022 | 2022-03-31 | −35.55% | −13.92 pp |
| Q4 2021 | 2021-12-31 | −48.52% | −1.75 pp |
| Q3 2021 | 2021-09-30 | −31.83% | −1.49 pp |
| Q2 2021 | 2021-06-30 | −16.35% | +20.04 pp |
| Q1 2021 | 2021-03-31 | −21.63% | +6.04 pp |
| Q4 2020 | 2020-12-31 | −46.77% | −3.15 pp |
| Q3 2020 | 2020-09-30 | −30.35% | −2.95 pp |
| Q2 2020 | 2020-06-30 | −36.39% | −25.68 pp |
| Q1 2020 | 2020-03-31 | −27.67% | −21.35 pp |
| Q4 2019 | 2019-12-31 | −43.62% | +939.94 pp |
| Q3 2019 | 2019-09-30 | −27.40% | −18.98 pp |
| Q2 2019 | 2019-06-30 | −10.71% | −12.08 pp |
| Q1 2019 | 2019-03-31 | −6.32% | −9.72 pp |
| Q4 2018 | 2018-12-31 | −983.56% | −981.92 pp |
| Q3 2018 | 2018-09-30 | −8.43% | −6.57 pp |
| Q2 2018 | 2018-06-30 | 1.37% | −6.80 pp |
| Q1 2018 | 2018-03-31 | 3.40% | −0.23 pp |
| Q4 2017 | 2017-12-31 | −1.64% | −17.49 pp |
| Q3 2017 | 2017-09-30 | −1.86% | −17.19 pp |
| Q2 2017 | 2017-06-30 | 8.17% | +80.02 pp |
| Q1 2017 | 2017-03-31 | 3.63% | −9.05 pp |
| Q4 2016 | 2016-12-31 | 15.85% | +71.52 pp |
| Q3 2016 | 2016-09-30 | 15.34% | +29.90 pp |
| Q2 2016 | 2016-06-30 | −71.85% | −25.79 pp |
| Q1 2016 | 2016-03-31 | 12.68% | +22.15 pp |
| Q4 2015 | 2015-12-31 | −55.67% | +427.23 pp |
| Q3 2015 | 2015-09-30 | −14.57% | +146.17 pp |
| Q2 2015 | 2015-06-30 | −46.06% | +166.22 pp |
| Q1 2015 | 2015-03-31 | −9.47% | +321.34 pp |
| Q3 2012 | 2012-09-30 | −482.90% | +78.84 pp |
| Q2 2012 | 2012-06-30 | −160.74% | +176.35 pp |
| Q1 2012 | 2012-03-31 | −212.28% | −161.39 pp |
| Q4 2011 | 2011-12-31 | −330.81% | +336.80 pp |
| Q3 2011 | 2011-09-30 | −561.74% | −23.45 pp |
| Q2 2011 | 2011-06-30 | −337.08% | — |
| Q1 2011 | 2011-03-31 | −50.89% | — |
| Q3 2010 | 2010-09-30 | −667.61% | — |
| Q2 2010 | 2010-06-30 | −538.29% | — |
Over the last five reported fiscal years, Sanara MedTech's operating margin increased from −32.30% to 7.08%, a change of +39.38 percentage points. The latest reported quarter, Q2 2026, shows 6.33%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanara MedTech filings at SEC.gov ↗